Literature DB >> 9769114

T cell-tumor cell: a fatal interaction?

D B Chappell1, N P Restifo.   

Abstract

Fas (Apo-1/CD95) is a cell-surface protein that is responsible for initiating a cascade of proteases (caspases) culminating in apoptotic cell death in a variety of cell types. The function of the Fas/FasL system in the dampening of immune responses to infectious agents through the autocrine deletion of activated T cells has been well documented. More recently, it has been proposed that tumor cells express FasL, presumably to avoid immune detection. In this review, we focus on the role of the interaction of Fas and FasL in the modulation of antitumor responses. We critically examine the evidence that FasL is expressed by tumor cells and explore alternative explanations for the observed phenomena in vitro and in vivo. By reviewing data that we have generated in our laboratory as well as reports from the literature, we will argue that the Fas/FasL system is a generalized mechanism used in an autocrine fashion to regulate cell survival and expansion in response to environmental and cellular cues. We propose that FasL expression by tumor cells, when present, is indicative of a perturbed balance in the control of proliferation while "immune privilege" is established by "suicide" of activated antitumor T cells, a form of activation-induced cell death.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9769114      PMCID: PMC2249694          DOI: 10.1007/s002620050505

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  54 in total

1.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

2.  TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation.

Authors:  M Sata; K Walsh
Journal:  Nat Med       Date:  1998-04       Impact factor: 53.440

3.  Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells.

Authors:  T Tamura; N Aoyama; H Saya; H Haga; S Futami; M Miyamoto; T Koh; T Ariyasu; M Tachi; M Kasuga
Journal:  Oncogene       Date:  1995-11-16       Impact factor: 9.867

4.  Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide.

Authors:  M R Young; M A Wright; J P Matthews; I Malik; M Prechel
Journal:  J Immunol       Date:  1996-03-01       Impact factor: 5.422

5.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

Authors:  N P Restifo; F M Marincola; Y Kawakami; J Taubenberger; J R Yannelli; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1996-01-17       Impact factor: 13.506

6.  Interfering with apoptosis: Ca(2+)-binding protein ALG-2 and Alzheimer's disease gene ALG-3.

Authors:  P Vito; E Lacanà; L D'Adamio
Journal:  Science       Date:  1996-01-26       Impact factor: 47.728

Review 7.  The Fas death factor.

Authors:  S Nagata; P Golstein
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

8.  Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35.

Authors:  N J Bump; M Hackett; M Hugunin; S Seshagiri; K Brady; P Chen; C Ferenz; S Franklin; T Ghayur; P Li
Journal:  Science       Date:  1995-09-29       Impact factor: 47.728

9.  Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV.

Authors:  M Zörnig; A Grzeschiczek; M B Kowalski; K U Hartmann; T Möröy
Journal:  Oncogene       Date:  1995-06-15       Impact factor: 9.867

10.  Metalloproteinase-mediated release of human Fas ligand.

Authors:  N Kayagaki; A Kawasaki; T Ebata; H Ohmoto; S Ikeda; S Inoue; K Yoshino; K Okumura; H Yagita
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  17 in total

1.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Authors:  V Bronte; D B Chappell; E Apolloni; A Cabrelle; M Wang; P Hwu; N P Restifo
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

3.  Prognostic significance of RCAS1 expression in relation to the infiltration of dendritic cells and lymphocytes in patients with esophageal carcinoma.

Authors:  Shunichi Tsujitani; Hiroaki Saito; Shinichi Oka; Teruhisa Sakamoto; Shingo Kanaji; Shigeru Tatebe; Masahide Ikeguchi
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

Review 4.  Sipuleucel-T: Prototype for development of anti-tumor vaccines.

Authors:  Estrella Carballido; Mayer Fishman
Journal:  Curr Oncol Rep       Date:  2011-04       Impact factor: 5.075

5.  The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma.

Authors:  Rathasapa Patarat; Shoji Riku; Pattapon Kunadirek; Natthaya Chuaypen; Pisit Tangkijvanich; Apiwat Mutirangura; Charoenchai Puttipanyalears
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

Review 6.  The Fas/Fas ligand system and cancer: immune privilege and apoptosis.

Authors:  Vikki M Abrahams; Marijke Kamsteeg; Gil Mor
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

7.  The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies.

Authors:  Zhizhong Zhang; Lixin Qiu; Meilin Wang; Na Tong; Jin Li; Zhengdong Zhang
Journal:  Eur J Hum Genet       Date:  2009-04-01       Impact factor: 4.246

Review 8.  Developing recombinant and synthetic vaccines for the treatment of melanoma.

Authors:  N P Restifo; S A Rosenberg
Journal:  Curr Opin Oncol       Date:  1999-01       Impact factor: 3.645

9.  Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.

Authors:  Shilpa Gupta; Estrella Carballido; Mayer Fishman
Journal:  Onco Targets Ther       Date:  2011-06-29       Impact factor: 4.147

Review 10.  The cancer stem cell: evidence for its origin as an injured autoreactive T cell.

Authors:  Peter Grandics
Journal:  Mol Cancer       Date:  2006-02-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.